Coexistence of synchronous bilateral Wilms tumor and trisomy 21 – first report and review of literature

Jure Pupić-Bakrač1*, Tomica Božić2, Ana Pupić-Bakrač3, Azer Rizikalo4, Petra Kovačević5

Abstract. Aim: The bilateral form of the Wilms tumor appears only in 5% of cases, and the incidence in children under the age of 15 is about 1: 250,000. Contrary to the expectations, large population-based studies have shown that the incidence of Wilms tumor is much lower in the population with trisomy 21 than in the general population. To our knowledge, this is the first reported case of synchronous bilateral Wilms tumor appearing in a patient with trisomy 21. Case report: A 19-month-old male, previously known for trisomy 21, was admitted to hospital because of chronic constipation and abdominal pain. He had the last stool seven days before the examination. Abdominal palpation in the left hypochondriac region revealed a solid mass of about 6x6 cm in size. Ultrasound and Multislice Computed Tomography showed a tumor on both kidneys; the right was smaller, and the left was larger – destroying most of the parenchyma and causing the bowel obstruction. After 3 weeks of chemotherapy, the radical left nephrectomy and the partial right nephrectomy were made. 28-week chemotherapy continued postoperatively. Histopathology tests confirmed the diagnosis of Wilms tumor. After recovery, the patient had a sufficient renal function. Conclusion: The conventional treatment with a combination of chemotherapy and surgical resection showed a good long-term outcome. However, in these cases a special caution should be focused on the quantity of preserved renal tissue, because of an increased risk of renal failure.

Coexistence of synchronous bilateral Wilms tumor and trisomy 21 – first report and review of literature

Jure Pupić-Bakrač1*, Tomica Božić2, Ana Pupić-Bakrač3, Azer Rizikalo4, Petra Kovačević5


Ključne riječi: Down sindrom; Wilms tumor

*Corresponding author:
Jure Pupić-Bakrač, MD
Department of Emergency Medicine
University Clinical Hospital Mostar
Bijeli brijeg bb, 88 000 Mostar
Bosnia and Herzegovina
e-mail: jureppbk2@gmail.com
INTRODUCTION

Wilms tumor (WT) is the most common intrabdominal malignancy in children (incidence of 1:10 000 in children before the age of 15 years), and there are 450-500 newly diagnosed cases of illness in the United States (US) every year\textsuperscript{1,2}. Contrary to the unilateral, bilateral form of malignancy is rare – it is reported in only about 5% of cases, or 1: 250,000 children before the age of 15 years\textsuperscript{3,4}. Most WT cases are sporadic, but in one

of ten cases WT is associated with genetic syndromes or other congenital malformations. In available literature, an increased incidence of WT is described in many syndromes, among others in: WAGR, Denys-Drash, Fraiser, Beckwith-Wiedemann, Trisomy 18, etc\textsuperscript{5}. Trisomy 21 generally has an increased risk of developing malignancies in relation to the risk for the general population. Results of previous studies have shown that patients with trisomy 21 karyotype have a 10-20 times higher risk of developing acute lymphoblastic and acute myeloid leukemia\textsuperscript{6,7}. As opposed, none of the studies showed an elevated risk of developing solid tumors. Contrary to expectations, large population-based studies and a review of tumor registers showed that the incidence of WT is lower in trisomy 21 patients than in general population\textsuperscript{8,9}. So far, several authors reported rare cases of WT appearing in the trisomy 21\textsuperscript{10,11}, but to our knowledge, not bilateral WT. Below we present a case of this rare and clinically challenging coexistence of trisomy 21 and malignancy on both kidneys.

CASE REPORT

A 19-months-old male was admitted to hospital due to chronic constipation and abdominal pain. The patient was the second child from second pregnancy. In the 33rd week of pregnancy the expectant mother was hospitalized for vaginal bleeding and polyhydramnion. During pregnancy there was no evidence of teratogen exposure. The baby was born by Caesarean section, one day before the estimated date of delivery. The mother was 41 years old and the father 55 years old. Birth weight was 3700 g, birth length 53 cm, Apgar score 10/10. Clinical examination of the newborn detected phenotypic features of Down syndrome. Cytogenetic analysis using GTG-banding technique confirmed trisomy 21 and karyotype was: 47,XY,+21. Screening on congenital malformations detected secundum atrial septal defect (7 mm), patent ductus arteriosus (3 mm) and umbilical hernia, which were regularly monitored. At age of 4 months, the diagnosis of primary hypothyroidism was established, and at age of 10 months, diagnosis of right hearing loss of 50%.

Patient was admitted to Department of Pediatrics because of abdominal pain and stool absence 7 days before the examination. It was acknowledged that the patient previously had stool every 3-4 days, but a month before the examination, he began to suffer pain and cry during defecation. There was no blood or mucus in the stool. He did not vomit and had no fever.

Clinical examination showed that abdomen was soft, diffuse painful on palpation, without peritoneal stimulation. Auscultation of abdomen showed normal peristalsis. Palpation in the umbilical region revealed reducible umbilical hernia and in left hypochondriac region solid formation measuring about 6x6 cm. Lumbar succion was negative. Examination of other body regions was without a pathological substrate. The vital parameters were within the normal range.

Results of laboratory tests (complete blood count (CBC), differential blood count (DBC), standard biochemical tests, urine) were within the reference values. Ultrasound of the abdomen showed tumor formation 31×27 mm in size in upper pole of right kidney, homogeneous (Figure 1). The left kidney was significantly reduced to a tumor formation sized 67×55 mm, homogeneous (Figure 2). Ultrasound did not show pathological substrates on other intraabdominal organs. The abdominal Multislice Computed Tomography (MSCT) scan showed the following specifics: in the cranial part of the right kidney naturally iso-
dense, and a postcontrastically moderately hypodense tumor formation, with well-limited edges, sized about 3.2 cm in largest diameter (Figure 3a); in the area of the left kidney, tumor formation of similar characteristics, sized 5-6.3 cm in diameter in transverse cross-sections, and 7.6 cm in the craniocaudal cross-section, which destroyed most of the left renal parenchyma and caused bowel obstruction (Figure 3b); within the described changes no signs of calcification; no ascites nor enlargement of the regional lymph nodes; other intraabdominal and intrapelvic organs without the presence of focal pathology.

Considering that described characteristics were suspicious on synchronous bilateral Wilms tumor, patient was transferred to a surgical reference center for pediatric solid tumors. Preoperatively, he received chemotherapy with Actynomicin D and Vincristin for 3 weeks, after which he underwent surgery. The operation was accessed with transverse subcostal incision. Enucleation of the tumor and partial nephrectomy (with the maintenance of 3/4 of renal parenchyma) on the right side, radical nephrectomy on the left side and exirpiration of paraaortic lymph nodes were performed. After the surgery, chemotherapy with Actynomicin D and Vincristin continued for 28 weeks. Histopathology confirmed diagnosis of bilateral Wilms tumor (stage I and II according to National Wilms Tumor Study (NWTS)). Cytogenetic analysis of tumor tissue was not performed. After recovery, the patient had a satisfactory renal function, with normal values of CBC, DBC, urea, creat-

Figure 1. Ultrasound scan of Wilms tumor in right kidney

Figure 2. Ultrasound scan of Wilms tumor in left kidney

Figure 3. MSCT of abdomen (transverse section); a) scan of Wilms tumor in right kidney – largest diametar; b) scan of Wilms tumor in left kidney – largest diametar
ine, minerals, C-reactive protein (CRP), urine and other parameters. He was discharged to home 18 days after surgery, with ordered regular oncological controls. In the 4-year follow up period he had a normal clinical course, without relapse of illness.

Patients with trisom 21 generally have a lesser reserve and the ability to adapt to renal tissue resection. Therefore, when performing unilateral radical nephrectomy, we recommend at least 3/4 of contralateral’s renal parenchyma to be preserved, unlike for the general population, where 2/3 is sufficient.

**DISCUSSION**

The occurrence of Wilms tumor in the population of trisomy 21 patients is a very rare phenomenon, and by reviewing literature we have found only two such reports. The exact incidence of WT in this group of patients is still unknown, but how rare its occurrence is, showed the research of authors from US, who analyzed the National Wilms Tumor Study Registers. Reviewing registers, they found 5854 cases of WT, none of which associated with trisomy 21. Considering the prevalence of trisomy 21 of 1: 660 in live-borns, at least 7.6 to 9.9 cases were expected. The possibility for a bilateral WT in trisomy 21 is minimal, and to our knowledge, no such case has been reported so far.

WT is a genetically heterogeneous neoplasia, characterized by a number of genetic abnormalities, involving tumor suppressor genes, oncogenes and genes related to the Wnt signaling pathway. For a long time only one WT gene was known – WT1 at 11p13. However, various studies discovered that WT1 is altered in only approximately 20% of WT. Recently a novel gene mutations of WTX at Xq11.1 and CTNNB1 at 3p22.1 were reported to be present in WT. WT1, WTX and CTNNB1 mutations account for the genetic basis of 30-50% of WT. Most of WT cases are sporadic, and approximately 5-10% of patients with WT have an underlying predisposing genetic syndrome. It is well known that genetic syndromes related to loci mapped to the short arm of chromosome 11 (WAGR, Denys-Drash, Frasier, Beckwith-Wiedemann) are characterized by an increased risk of WT. Several 11p-linked syndromes result from a disruption of the WT1 gene, which encodes the transcription factor WT1, crucial for renal and gonadal embryogenesis. Disruption of the WT1 gene typically results in genitourinary abnormalities and predisposition to early WT (almost always under five years of age), often associated with intralobar and rhabdomyoblastic change within the tumor.

Microdeletion of the WT1, along with the neighbouring PAX6 leads to WAGR syndrome, missense mutations of the WT1, typically in the zinc finger domains, result in Denys-Drash syndrome, and WT1 mutation in intron 9 can result in abnormal splicing leading to Frasier syndrome. In Beckwith-Wiedemann syndrome different chromosomal region – 11p15 band (WT2 locus) is disrupted in a number of ways, most commonly as a result of hypomethylation or uniparental disomy. Non 11p-linked syndromes are less often associated to WT, and their specific co-occurrence remains unclear. Some non 11p-linked syndromes, such as Perlman syndrome, Sotos syndrome, Simpson-Golabi-Behmel syndrome, Bloom syndrome, Li-Fraumeni syndrome, trisomy 18 etc., have a slightly higher incidence of WT compared to general population; and some, such as trisomy 21, have lower. Various theories explain generally decreased incidence of solid tumors in trisomy 21 by enhanced expression of tumor suppressor genes on chromosome 21. Endostatin – protein that inhibits angiogenesis and neoplastic growth in human and animal models is encoded by the COL18A1, which is located on the chromosome 21. S-100b protein, also encoded by one of the genes on chromosome 21, inhibits growth and induces apoptosis of human and murine neuroblastoma cell lines. Both endostatin and S-100b protein have increased level in the blood of trisomy 21 patients, compared to general population. Other potentialy protective chromosome 21 genes include DCRS-1 gene and ETS 2 oncogene, which block blood vessel formation and tumor development in murine models of DS.

In clinical terms, the bilateral form of WT is a major therapeutic challenge. So far, there have not been unique attitude in the surgical community.
about the treatment strategy for the occurrence of malignancy in both kidneys. Nowadays, most clinic centers practice preoperative treatment with chemotherapy/radiotherapy (for tumor tissue reduction), as well in the postoperative period. Some authors prefer expolarization and biopsy of renal parenchyma and regional lymph nodes before the definitive surgery, but such an approach is often avoided because of the risk of the formation of tumor fragments and potential iatrogenic metastases. As for the surgical approach, there are several surgical resection techniques, and most commonly used are: unilateral radical nephrectomy with contralateral partial nephrectomy (with preservation of at least 2/3 renal parenchyma), bilateral partial nephrectomy, and unilateral radical nephrectomy with aggressive chemotherapy and radiation of the contralateral kidney. The common feature of all of these approaches is surgery of preservation, with the aim of preserving adequate long-term renal function. Our attitude is that there is no optimal approach for all bilateral WT, because the manifestation of the illness is unique in each patient, so the treatment should be individually adjusted too. In our case, WT caused complete tissue destruction on one kidney, while on the other kidney it was localized and limited from healthy tissue. Given the sufficient amount of renal parenchyma on right kidney, the approach with unilateral radical and contralateral partial resection was a logical solution. In the postoperative period of 4 years, patient had no complications, and we can conclude that we have accomplished a task of satisfying both criteria – complete extirpation of pathological tissue and maintaining an adequate kidney function. However, monitoring of these patients should be lifelong, because WT can relapse after several years, and renal function can worsen – even 20 or more years after diagnosis (patients with genetic syndromes in basics have lower renal function compared to non-syndromes population).

**CONCLUSION**

Considering that many congenital urological defects have been associated with trisomy 21, an underrepresentation of WT diagnosis is very interesting. This case demonstrates that, although probability is low, synchronous bilateral WT can occur in trisomy 21 patients. Like in the general population, treatment with a combination of chemotherapy and surgical resection showed good long-term outcome. However, preservation of renal tissue should be carefully planned because this patients have lower functional reserve. Apart from establishing clinical approach to treatment, informations on various cases of solid tumors in trisomy 21 could have a great value in discovering etiopathogenesis of cancer, especially WT which is genetically heterogeneous.

**REFERENCES**


**Conflicts of interest statement:** the authors report no conflicts of interest.